leisure time -WSS

leisure time

author：leisure time 2025-09-30 16:25:02 - browse：78264

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Medical records are filled with copy
Next article： Medicare Advantage beneficiaries sue Humana over algorithm use

focus

leisure time

knowledge

WSS

CRISPR gene editing developments we’re watching in 2024

What is artificial intelligence? Experts weigh in

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Hey, doctors: Don't be no

Why health care costs have stayed mostly flat since 2010

HCA sued by state AG for quality issues at Mission Health

entertainment

leisure time

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Virtual care provider acquires bankrupt Pear's prescription apps

Activists slam private health insurers over coverage restrictions

Hospitals owned by private equity see complications spike 25%

Hepatitis C has a cure — but many Americans still lack access to it

New chief aims to remake Sanofi Genzyme

New air purifier tech could be key to improving indoor air quality

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Novavax promises a turnaround & Lilly roils the obesity market

How Brent Saunders' Allergan experiment failed

focus

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

SEC charges former device maker CEO with $41 million fraud

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Virtual care provider acquires bankrupt Pear's prescription apps

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

SEC charges former device maker CEO with $41 million fraud

focus

leisure time

knowledge

explore